Diagnosis and medical management of abnormal premenopausal and postmenopausal bleeding

Black, Denise

doi:10.1080/13697137.2023.2178893

Cited by 2 publications

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Any bleeding following the first six months of therapy needs to be adequately investigated. 17 If thorough investigations are negative and bleeding persists, switching to CE/BZA (in patients not considered at increased VTE or CVD risk) may alleviate the bleeding issues. 18 Mastalgia is a common side effect during the initial three months of EPT use, with rates approaching 25%.…”

Section: Managing Side Effectsmentioning

confidence: 99%

Menopause Hormone Therapy: 2023 Update

Black

2023

Can Prim Care Today

View full text Add to dashboard Cite

The publication of the Women’s Health Initiative (WHI) study in 2002 caused a precipitous decline in use of menopause hormone therapy (MHT). Prior to publication, approximately 43% of women aged 45–74 used MHT; following publication, this number dropped to 11%. Fear of breast cancer was the largest motivator behind this decline. Since the WHI study, menopause medical education has been inadequate; it is estimated that 41% of medical schools do not include menopause education in their undergraduate curriculum. The same study highlighted significant knowledge gaps regarding menopause management among practicing physicians. Menopausal women are asking questions and expecting answers. Advocacy groups such as the Menopause Foundation of Canada are empowering women to acknowledge the impact of menopausal symptoms on the workplace, personal relationships and personal health. As MHT is considered first-line therapy (in the absence of contraindications), it behooves healthcare providers to have a working knowledge of MHT.

show abstract

Section: Managing Side Effectsmentioning

confidence: 99%

Menopause Hormone Therapy: 2023 Update

Black

2023

Can Prim Care Today

View full text Add to dashboard Cite

show abstract

Transarterial embolization of uterine arteries in emerging dysfunctional uterine bleeding: a single-center case series study

El Zaeem Esmaeel,

Fouad AbdelBaki Allam,

Aboulfotouh Elsayed Mourad

et al. 2024

Egypt J Radiol Nucl Med

View full text Add to dashboard Cite

Background Uterine artery embolization is proven to be an effective treatment for symptomatic uterine fibroids. Yet, its role in the management of dysfunctional uterine bleeding is still debatable. Patients with dysfunctional uterine bleeding have abnormal bleeding from the uterine vascular bed with variable underlying mechanisms. Uterine artery embolization will reduce/prevent bleeding by occlusion of the vascular bed, with subsequent cutoff of the effect of hormones on the endometrium. The aim of this work is to demonstrate the safety, efficacy and possible short-term complications of uterine artery embolization in the treatment of dysfunctional uterine bleeding (DUB) as a first-line treatment modality rather than the current treatment options (hormonal and surgical treatment). Methods Thirty patients included in the study were clinically and laboratory diagnosed based on FIGO classification system (PALM-COEIN) as DUB, and the diagnosis was confirmed by MRI imaging. All patients were subjected to transcatheter uterine artery embolization with subsequent clinical and radiological follow-up to assess the treatment outcome. Results Uterine artery embolization was able to control bleeding in patients diagnosed as DUB, with subsequent complete cessation of medical treatment; no surgical interference was needed with much less morbidity. We had 93.3% improvement in the frequency, volume of bleeding and 100% improvement of the presenting anemia. No significant change in uterine volume or in endometrial thickness has been noted. Conclusions Uterine artery embolization is safe, effective procedure to control dysfunctional uterine bleeding with the preservation of the uterus especially in critical age groups.

show abstract

Diagnosis and medical management of abnormal premenopausal and postmenopausal bleeding

Cited by 2 publications

References 37 publications

Menopause Hormone Therapy: 2023 Update

Menopause Hormone Therapy: 2023 Update

Transarterial embolization of uterine arteries in emerging dysfunctional uterine bleeding: a single-center case series study

Contact Info

Product

Resources

About